NPX-101 is a portable home device for the treatment of moderate to severe depression, boasting more effective and safer outcomes, based on information deposited and received from the Cloud.

Informazioni relative al progetto

NPX-101

ID dell’accordo di sovvenzione: 728611

DOI 10.3030/728611

Progetto chiuso

Data della firma CE 26 Luglio 2016

Data di avvio 1 Giugno 2016

Data di completamento 30 Settembre 2016

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale € 71 429,00

Contributo UE € 50 000,00

Coordinato da

NEUROPREX EUROPE INC LTD
United Kingdom

Obiettivo

Over 450 million individuals face depression, with over 800,000 suicide deaths per year, delivering a death rate of one person every 40 seconds. These figures are set to increase as estimates put 1 out of 4 individuals in the future to face similar mental disorders at some stage of life.
NPX-101 is the first product line for treating moderate to severe depression, especially the 30% of patients who are currently drug-resistant. It is a patented non-invasive bioelectronic device that delivers Transcranial Magnetic Stimulation (TMS) in the form of a wearable Magnetic Resonance Imaging (MRI) helmet with shield protection. It delivers more precise and deeper energy stimulation, for fuller more effective therapy, removing the side-effects and other treament discomforts with current day treatment. Phase 1 of the SME instrument fits into the overall company plan of NeuroPrex and Omsbar to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of the NPX-101. It would importantly help to deduce the quickest routes of distribution and market uptake for its entry-point of the U.K.

Campo scientifico

• medical and health sciences › basic medicine › neurology › dementia › alzheimer
• social sciences › psychology › psychotherapy
• medical and health sciences › clinical medicine › psychiatry › posttraumatic stress disorder
• engineering and technology › medical engineering › diagnostic imaging › magnetic resonance imaging
• medical and health sciences › basic medicine › neurology › parkinson

Programma(i)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.4. - Active ageing and self-management of health
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
• H2020-EU.3.1.6. - Health care provision and integrated care

Argomento(i)

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well

Invito a presentare proposte

H2020-SMEInst-2016-2017

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEINST-1-2016-2017

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

NEUROPREX EUROPE INC LTD

• Contribution nette de l'UE: € 50 000,00
• Indirizzo: 72 GREAT SUFFOLK STREET ; SE1 0BL LONDON ; Regno Unito
• PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì:
  Regione
  London › Inner London — East › Lewisham and Southwark
• Regione: London › Inner London — East › Lewisham and Southwark
• Tipo di attività: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Costo totale: € 71 429,00

Partecipanti (1)

OMSBAR LIMITED

Regno Unito

• Contribution nette de l'UE: € 0,00
• Indirizzo: 5 THE CHAMBERS, VINEYARD, ABINGDON ; OX14 3PX OXFORDSHIRE
• PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì:
  Regione
  South East (England) › Berkshire, Buckinghamshire and Oxfordshire › Oxfordshire
• Regione: South East (England) › Berkshire, Buckinghamshire and Oxfordshire › Oxfordshire
• Tipo di attività: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Costo totale: Nessun dato